Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Loss-of-function mutations in IFNAR2 in COVID-19 severe infection susceptibility

Sandra P. Smieszek*, Vasilios M. Polymeropoulos, Changfu Xiao, Christos M. Polymeropoulos, Mihael H. Polymeropoulos

Vanda Pharmaceuticals Inc., 2200 Pennsylvania NW, Suite 300-E, Washington, DC 20037, USA

A R T I C L E   I N F O

Keywords: IFN, IFNAR, COVID-19, Therapeutics, Whole-genome sequencing, Viral genetics, Viral resistance

A B S T R A C T

Recent COVID-19 (coronavirus disease 2019) host genetics studies suggest enrichment of mutations in genes involved in the regulation of type I and type III interferon (IFN) immunity in patients with severe COVID-19 infection. We performed whole-genome sequencing analysis of samples obtained from patients participating in the ongoing ODYSSEY phase 3 study of hospitalised patients with severe COVID-19 infection receiving supplemental oxygen support. We focused on burden testing of categories of rare and common loss-of-function (LOF) variants in all of the IFN pathway genes, specifically with MAF < 0.1% and MAF < 1%. In a model including LOF and missense variants (MAF < 1%), we report a significant signal in both IFNAR1 and IFNAR2. We report carriers of rare variants in our COVID-19 cohort, including a stop-gain IFNAR2 (NM_000874:exon9:c.C966A:p.Y322X) amongst carriers of several other IFNAR2 rare non-synonymous variants. Furthermore, we report an increased allelic frequency of common IFNAR2 variants in our data, reported also by the COVID-19 Host Genetics Initiative.

© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Innate interferons (IFNs α/β and λ) play a major role in the induction and amplification of a crucial antiviral programme in response to viral infections. Specifically, type I IFNs play a crucial role in early-phase antiviral defence, whereas cytokines/chemokines are associated with induction of later inflammatory responses and the cytokine storm [1]. Recently, Zhang et al. reported enrichment of mutations in genes involved in the regulation of type I and type III IFN immunity in patients with severe COVID-19 (coronavirus disease 2019) [2]. Furthermore, van der Made et al. reported four young male patients with severe COVID-19 with predicted loss-of-function (pLOF) and missense variants in Toll-like receptor 7 (TLR7) associated with impaired IFN responses [3]. The high-affinity interferon α/β receptor IFNAR2 --/- genotype is associated with higher rates of influenza A virus (IAV) infection but decreased susceptibility to bacterial superinfection post IAV infection [4]. A recent study reported 50 COVID-19 patients with significantly impaired type I IFN activity, suggesting that type I IFN deficiency in the blood may be a hallmark in severe COVID-19 patients [1].

We have performed whole-genome sequencing (WGS) analysis on samples obtained from patients participating in the ongoing ODYSSEY - phase 3 randomised study of tradipitant in hospitalised patients with severe COVID-19 who are receiving supplemental oxygen support. The cohort of severe hospitalised COVID-19 cases was multi-ethnic, with an age range of 35–87 years (68% male, 32% female). We first focused on loss-of-function variants (rare pLOF) in all of the IFN genes as described in Zhang et al. [2]. We performed burden testing of categories of rare LOF variants in all the IFN pathway genes, specifically MAF < 0.1% and MAF < 1%. Whereas we did not detect pLOFs in the MAF < 0.1% category, in MAF < 1% in a model including LOF and missense variants, we see a significant signal in IFNAR1 and IFNAR2 (Table 1).

A detailed description of the methods is provided in the Supplementary Material.

We report carriers of these variants in IFNAR2 (NM_000874:exon9:c.C966A:p.Y322X) and IFNAR1 (NM_000629:exon9:c.A1264C:p.S422R) in our COVID-19 cohort (amongst other rare nonsynonymous variants not tested functionally). IFNAR2 Tyr322Ter is rare in general population, with 11 homozygous individuals reported among approximately 125 000 reference genomes in The Genome Aggregation Database (gnomAD). All 11 homozygous individuals were of East Asian descent with minor allele frequency of 0.03787

* Corresponding author.
E-mail address: sandra.smieszek@vandapharma.com (S.P. Smieszek).

https://doi.org/10.1016/j.jgar.2021.06.005
2213-7165/© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Table 1

| Gene   | MAF, gnomAD_GENOME_ALL < 1% (n = 50) | Any missense, splicing, pLOF (n = 1876) | OR       | 95% CI  | Z   | P-value | P-value (Fisher) |
|--------|-------------------------------------|--------------------------------------|----------|--------|-----|---------|-----------------|
| IFNAR1 | 4                                   | 15                                   | 10.7884  | 3.4466-33.7696 | 4.09 | <0.0001 | 0.0010845       |
| IFNAR2 | 4                                   | 50                                   | 10.5855  | 3.8187-33.1351 | 4.05 | 0.0001  | 0.037353        |
| IFNAR3 | 1                                   | 80                                   | 113.727  | 4.5755-282.7680 | 2.89 | 0.0039  | 0.025961        |
| IRF3   | 3                                   | 78                                   | 3.4417   | 0.4481-4.8315  | 0.64 | 0.5244  | 0.1961          |
| IRF7   | 1                                   | 20                                   | 2.6144   | 0.2176-12.4211 | 0.48 | 0.6298  | 0.34314         |
| STAT1  | 1                                   | 6                                    | 6.3465   | 0.751453.8430  | 1.7  | 0.0896  | 0.15565         |
| STAT2  | 2                                   | 65                                   | 3.7993   | 1.5631-9.2346  | 2.95 | 0.0032  | 0.0009853       |
| TBK1   | 1                                   | 2                                    | 19.1224  | 1.7052-214.4648 | 2.39 | 0.0167  | 0.073966        |
| TICAM1 | 1                                   | 60                                   | 0.6717   | 0.0839-4.5483  | 0.47 | 0.6362  | 0.32894         |
| TLR3   | 1                                   | 76                                   | 0.4834   | 0.0659-3.5472  | 0.72 | 0.4747  | 0.27071         |
| TRAF3  | 1                                   | 6                                    | 3.6305   | 0.751453.8430  | 1.7  | 0.0896  | 0.15565         |

OR, odds ratio; CI, confidence interval.

Compared with an overall population frequency of 0.00283 (gnomAD). For this stop–gain, we report (based on our WGS samples) a MAF of 0.009 versus 0.0013 in our controls.

Our findings are consistent with reports where genome-wide association studies have shown associations of IFNAR2 polymorphisms with severe infections, including COVID-19 infection [2]. For the missense variant in IFNAR1 (NM_000629:exon9:c.A1264C:p sapiens, Zhang et al. transiently transfected the fibroblast cell line SV40 (with overexpression of the variant) and stimulated with IFN α2 or IFNγ and reported a significant change of phosphorylation status of STAT1, compared with the wild-type. In our cohort, both carriers (heterozygotes) were female, survivors, aged >75 years (plasma IFN-γ levels of 9.6 pg/mL and below the limit of quantification). The key rare pLOF and missense variants are shown in Fig. 1. Furthermore, we report increased allelic frequency on common IFNAR2 variants in our data, as also reported by the COVID-19 Host Genetics Initiative. We specifically focused on rs12482556 reported as the second highest significant signal in the latest COVID-19 Initiative results [5]. In our cohort, we report a global MAF of 0.44 versus 0.32 in our 100 Genomes controls as well as a gnomAD global MAF of 0.31. Variants detected have previously been associated with risk of susceptibility to hepatitis B (rs2229207) and herpes simplex encephalitis (rs151272128). For rs2229207, we show the respective levels of IFNγ across genotypes (Fig. 1) with minor allele showing lower levels of IFNγ.

IFNAR2 LOF mutations including Tyr322Ter may increase susceptibility to severe COVID-19 infection especially among Asian-descent populations where the mutation is more prevalent. We also make the observation that the IFNAR2 Tyr322Ter homozygous state may explain the increased mortality associated with MMR (measles, mumps and rubella) vaccination in Japan that led to the discontinuation of the triple live-attenuated virus vaccine in that country [6]. Notably, IFNAR2 LOF mutation was reported in a young child with post-MMR vaccination encephalitis [6]. Given that high-affinity IFNAR2 as well as components of its downstream signalling (TYK2, STAT1 and STAT2) are all implicated in viral resistance, the natural corollary would be potential negative effects of JAK/STAT inhibitors such as some current treatments for atopic dermatitis or rheumatoid arthritis in the presence of LOF or other missense variations. Our findings are consistent with reports where genome-wide association studies have shown associations of IFNAR2 polymorphisms with severe infections, including COVID-19. Type I IFNs became one of the more promising potential drug candidates for COVID-19, with initial clinical trials showing preliminary results in reducing the severity of the disease [7]. We believe further dissemination of such WGS studies will enable quicker understanding of the nature of this heterogeneous host–virus interaction and especially of the severe manifestation of this infection.

Declaration of Competing Interests

Authors are employees of Vanda Pharmaceuticals.

Funding

None.

Ethical approval

All patients consented to the study. The study was reviewed and approved by Advarra IRB; Pro00043096.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jigar.2021.06.005.

References

[1] Liu BM, Martins TB, Peterson IJ, Hill HR. Clinical significance of measuring serum cytokine levels as inflammatory biomarkers in adult and pediatric COVID-19 cases: a review. Cytokine 2021;142:155478. doi:10.1016/j.cyto.2021.155478.
[2] Zhang Q, Bastard P, Liu Z, Le Pes J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020;370:eabb4570. doi:10.1126/science.abb4570.
[3] van der Made CI, Simons A, Schuurs-Hoejemakers J, van den Heuvel G, Mantere T, Kersten S, et al. Presence of genetic variants among young men with severe COVID-19. JAMA 2020;324:663–73. doi:10.1001/jama.2020.13719.
[4] Shepardson KM, Larson K, Johns LL, Stanek K, Cho H, Wellman J, et al. IFNAR2 is required for anti-influenza immunity and alters susceptibility to post-influenza bacterial superinfections. Front Immunol 2018;9:2589. doi:10.3389/fimmu.2018.02589.
[5] COVID-19 Host Genetics Initiative. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J Hum Genet 2020;28:715–18. doi:10.1038/s41438-020-0636-6.
[6] Duncan CJA, Mohammad SMB, Young DF, Skelton AJ, Leahy TR, Munday DC, et al. Human IFNAR2 deficiency: lessons for antiviral immunity. Sci Transl Med 2015;7 ra707ra154. doi:10.1126/scitranslmed.aac2227.
[7] Schreiber G. The role of type I interferons in the pathogenesis and treatment of COVID-19. Front Immunol 2020;11:595739. doi:10.3389/fimmu.2020.595739.